Merck antibody leads to reduced risk of Clostridium difficile recurrence
September 23, 2015
Permalink
Health

Merck antibody leads to reduced risk of Clostridium difficile recurrence

Results showed that following 12 weeks of treatment with the antibody and a single infusion…

Continue Reading →

Merck’s bezlotoxumab successful in two late-stage studies for prevention of C
September 22, 2015
Permalink
Health

Merck’s bezlotoxumab successful in two late-stage studies for prevention of C

Bezlotoxumab was developed by researchers at the University of Massachusetts Medical School’s MassBiologics Laboratory in…

Continue Reading →